The importance of the association between early lymphocyte recovery and outcome has not been well studied in autologous stem cell transplantation (ASCT). In this retrospective study, we analyzed 90 consecutive patients with non-Hodgkin's and Hodgkin's lymphoma who underwent ASCT. Patients were divided into two groups: group 1 with absolute lymphocyte count (ALC) on day +15 below the median of 667/mm 3 , and group 2 with ALC X667/mm 3 . The median progression-free survival (PFS), but not overall survival (OS), was significantly longer in group 2 when compared to group 1 (16 months vs not reached P ¼ 0.02). Group 2 patients also had significantly shorter hospital stay, received higher CD34 + cell dose, and had shorter time to neutrophil recovery. Multivariate analysis demonstrated day +15 ALC to be an independent prognostic indicator for PFS, but not OS, while CD34 + cell dose and the number of pretransplant treatments were better predictors for both PFS and OS. We conclude that higher day +15 ALC may independently predict better PFS after ASCT for lymphoma patients; however, whether this merely reflects faster overall recovery caused by higher infused CD34 + cell dose and less pretransplant therapy needs further investigation. Bone Marrow Transplantation (2003) 31, 1009-1013. doi:10.1038/sj.bmt.1704050 Keywords: autografting; lymphocyte recovery; lymphoma; stem cell transplant Autologous stem cell transplantation (ASCT), as compared to salvage chemotherapy in patients with relapsed, chemotherapy-sensitive Hodgkin's (HD) and non-Hodgkin's lymphoma (NHL), has been shown to be a superior modality of therapy in terms of progression-free survival (PFS) and overall survival (OS).
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We performed a retrospective study to analyze the significance of ALC at day +15 post-ASCT for patients with HD and NHL in relation to OS, PFS, time to absolute neutrophil count (ANC) recovery, incidence of infections, CD34 + cell dose administered, and length of stay in the bone marrow transplant unit (BMTU).
Patients and methods

Patient population
We analyzed 90 consecutive patients (32 with HD and 58 with NHL) who underwent ASCT at The University of Florida, BMT Service, during the period of January 1996 through December 2000. All patients signed Institutional Review Board-approved informed consents at the time of enrollment on the transplant treatment protocols. Data were obtained by review of computerized medical records. No patient was excluded.
Patient data
Patient characteristics and prognostic variables were retrieved and analyzed, including age at the time of transplant, gender, histological classification of lymphoma, status of disease at transplant, stage of disease, time from disease diagnosis to transplant, conditioning regimen, number of pretransplant treatments (chemotherapy regimens or radiation therapy), presence of (BM) involvement at transplant, CD34
+ cell dose administered, number of days to achieve ANC of X0.5 Â 10 9 /l, and platelet count of X20 Â 10 9 /l, ALC on day +15, OS, PFS, number and type of documented infections in the first 180 days post-ASCT. Patients were divided into two groups based on the median ALC on day +15 after ASCT: group 1 with ALCo667/ mm 3 , and group 2 with ALC X667/mm 3 .
Statistical analysis
OS and PFS times were analyzed using the method described by Kaplan and Meier, and the significance for differences in OS and PFS between the two groups was determined using log-rank test. We performed univariate logistic-regression analyses of these outcomes and 15 relevant clinical variables. Cox proportional regression hazards models were performed using only variables that were significant on univariate analysis. Hazard ratios (HRs), 95% confidence intervals (CI) and P-values were calculated. t-Student independent test and w 2 were used to analyze differences between the two groups, with statistical significance determined at Po0.05. The statistical analysis was performed using Statistica software for Windows (Statsoft, Inc., 2000, Tulsa, OK, USA).
Results
Patient characteristics and engraftment parameters
Of all patients, 78 (87%) received autologous peripheral blood stem cell transplant, nine (10%) received both autologous BM and peripheral blood (PB) stem cell transplant, three (3%) received CD34+ selected PB autograft, and no patients received only BM. Patients who received both BM and PB stem cells were mostly patients who enrolled on an earlier study in which patients received the products of BM harvest and two 10-l aphereses. Out of 90 (59%) patients, 53 were treated with conditioning regimen containing busulfan, cyclophosphamide, and etoposide, 26 (27%) received thiotepa, carboplatin, and cyclophosphamide, and 11 (14%) patients were treated with other conditioning regimens. There were no statistical differences between the two groups regarding the type of conditioning regimen used, presence of BM involvement prior to transplant, age, gender, type of disease, status of disease at transplant, lactate dehydrogenase levels (LDH), number of pretransplant treatments, time from diagnosis to transplant (Table 1 ). In addition, there was no statistically significant difference in the distribution of the two main conditioning regimens among HD vs NHL patients. Patients in group 2 had shorter median length of stay in BMT unit (22 vs 23 days, P ¼ 0.038), received higher CD34 + cell dose (median of 4.7 vs 3.8 Â 10 6 /kg/ideal body weight; P ¼ 0.02), and had shorter median time to ANC recovery of X500/mm 3 (11 vs 12 days; P ¼ 0.04) ( Table 1) .
In order to investigate whether faster ALC recovery is related to the transplanted CD34 + cell dose, Kendall's rank analysis was performed, which showed significant correlation between the two (P ¼ 0.05).
We examined the incidence and type of microbiologically documented infections encountered between the two groups of patients. The incidence of bacteremia within 30 days post-ASCT was 18% for group 1 and 15% for group 2. Interestingly, eight and two patients in groups 1 and 2, respectively, had herpes zoster exacerbation (P ¼ 0.08) within 180 days post-ASCT. One episode of fungemia was diagnosed in each group.
Survival analysis
No deaths occurred before day +15. Survival analysis (Figure 1a ) reveals that the median PFS for patients in group 1 was 16 and statistically significantly shorter (not reached) for patients in group 2. The OS for both groups 1 and 2 (median not reached) was not statistically different (P ¼ 0.27) (Figure 1b) . Similar analysis using day +15 ALC of 500 or 750/mm 3 also showed significantly improved PFS (P-values of 0.047 and 0.008, respectively), and a higher trend towards better OS (P-values of 0.25 and 0.13, respectively).
In univariate analysis, several prognostic factors (all those in Table 1) including day +15 ALC were tested as predictors for OS and PFS for all the study patients. Day +15 ALC, number of pretransplant treatments, and CD34 + cell dose administered were significant predictors of PFS, while only the latter two were significant predictors for OS (Table 2 ). Since Porrata et al 10 included only NHL without HD patients in their analysis, we performed separate analysis for NHL patients only, which revealed that day +15 ALC (P ¼ 0.05) and CD34 + cell dose (P ¼ 0.005) are significant predictors for better PFS. However, again only CD34 + cell dose was a significant predictor for better OS (P ¼ 0.01).
In multivariate analysis (Table 3) , day +15 ALC was again an independent prognostic factor for PFS (HR ¼ 0.417, CI 95% ¼ 0.21-0.84, P ¼ 0.014), but not for OS (P ¼ 0.49), when compared to the other significant predictors identified by univariate analysis. This signifi- cance persisted even when patients received 45 Â 10 6 CD34 cells/kg. On the other hand, both CD34
+ cell dose and the number of pretransplant treatments were independent predictors for PFS (P ¼ 0.0449 and 0.0011, respectively) and stronger predictors for OS (P ¼ 0.0025 and 0.0025, respectively).
Discussion
Our study demonstrates that lymphoma patients with ALC X667/mm 3 on day+15 had significantly better PFS and a positive trend towards improved OS. Our analysis demonstrates that patients in Group 2 with higher day +15 ALC also had significantly higher transplant CD34 + cell dose, shorter time to ANC recovery, and shorter length of hospital stay (Table 1) . We have previously reported that lymphoma patients with poor peripheral blood stem cell mobilization had a worse outcome after ASCT mainly because of disease relapse. 11 Therefore, one may conclude that the use of higher CD34
+ cell dose in autografting is essential for faster immune recovery and better outcome. Corroborating such hypothesis is a recent report showing that outcomes after syngeneic BMT could be improved by transplanting more than 3 Â 10 8 nucleated cells/kg. 12 The importance of early lymphocyte recovery has been well characterized in the allogeneic BMT setting for the management of some hematological malignancies. 8, 9 In autologous transplantation, however, data on such association have become available only recently. Porrata et al 10 analyzed the correlation of early lymphocyte recovery (day +15 post-ASCT) and clinical outcome in 230 patients (MM ¼ 126 and NHL ¼ 104) who underwent ASCT for relapsed chemotherapy-sensitive disease. The median OS and PFS times for patients with MM and NHL were significantly longer in patients with ALCX0.5 Â 10 9 /l than patients with ALCo0.5 Â 10 9 /l. Multivariate analysis revealed that day +15 ALC was an independent important prognostic indicator for OS and PFS for both the disease categories. Although our results support Porrata et al conclusions, the data we present here suggest that the CD34 + cell transplant dose and the extent of pretransplant therapy may be important determinants in faster lymphocyte recovery after ASCT. The day +15 ALC was significantly predictive for better PFS, but not OS, in univariate and multivariate analyses. This discordance is most likely related to the relatively low number of patients in the two groups of patients compared and possibly the duration of follow-up.
The recovery of the different components of the immune system after autografts has been well studied. [12] [13] [14] [15] [16] [17] [18] Functional immune recovery occurs gradually over several months to a year post-ASCT, and its components consist of: (1) reappearance of functional B-cells, (2) thymic and extra-thymic T-cell development, and reconstitution of effector cells including cytotoxic T cells and natural killer (NK) cells, and (3) efficient antigen presentation mechanisms. Traditionally, the recovery of absolute neutrophil and platelet counts has been considered a significant end point in hematological recovery post-ASCT. In view of our results, the results of Porrata et al, and what is known about the functional immune recovery, ALC may become another important end point for engraftment and recovery after ASCT. The mechanisms of early lymphocyte count recovery and its effect on improved outcome remain to be elucidated. One may postulate that early lymphocyte recovery results in improved immunological activity against residual disease, analogous to graft-versus-tumor effect observed after allogeneic stem cell transplantation.
In conclusion, we confirm the association between early lymphocyte recovery and improved clinical outcome in lymphoma patients, both Hodgkin's and non-Hodgkin's, undergoing ASCT. However, our results also show that early recovery of ALC may reflect the transplant CD34 + cell dose and prior therapy, thus resulting in faster immune recovery and better outcome. Therefore, patients with lower cell dose because of poor mobilization may benefit from new approaches to enhance immune reconstitution. Examples for such approaches could include improved mobilization methods to obtain higher CD34 + dose, early collection of CD34 + stem cells in the course of therapy for high-risk lymphoma patients, and/or the use of post-ASCT cytokines to enhance immune recovery, or both. Since the limitations of a retrospective analysis, our results should be viewed with caution and prospective studies that attempt to link functional recovery of specific lymphocyte subsets and outcome are needed before any firm conclusions are made. 
